CRDF Q1 2025 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$109,000-46.8% YoY

Gross Profit

$109,000100.0% margin

Operating Income

-$14M-13194.5% margin

Net Income

-$13M-12324.8% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-27.8%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$85M

Total Liabilities

$14M

Stockholders' Equity

$71M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$109,000	$205,000	-46.8%
Gross Profit	$109,000	$103,000	+5.8%
Operating Income	-$14M	-$11M	-31.5%
Net Income	-$13M	-$10M	-34.2%